Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion.

[1]  P. van Eyken,et al.  In situ localization of melanotransferrin (melanoma-associated antigen P97) in human liver. A light- and electronmicroscopic immunohistochemical study. , 2008, Liver.

[2]  R. Béliveau,et al.  Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. , 2005, Biochimica et biophysica acta.

[3]  W. Jefferies,et al.  Deletion of the GPI pre-anchor sequence in human p97--a general approach for generating the soluble form of GPI-linked proteins. , 2004, Protein expression and purification.

[4]  R. Béliveau,et al.  Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. , 2003, Blood.

[5]  M. Ranson,et al.  Plasminogen binding and cancer: promises and pitfalls. , 2003, Frontiers in bioscience : a journal and virtual library.

[6]  J. Rakic,et al.  Role of plasminogen activator-plasmin system in tumor angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.

[7]  Y. Takada,et al.  Plasmin-induced Migration of Endothelial Cells , 2002, The Journal of Biological Chemistry.

[8]  D. Richardson,et al.  The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein. , 2002, European journal of biochemistry.

[9]  Ping Wang,et al.  The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. , 2002, Biochimica et biophysica acta.

[10]  D. Richardson,et al.  A second melanotransferrin gene (MTf2) and a novel protein isoform: explanation for the membrane‐bound and soluble forms of melanotransferrin? , 2002, FEBS letters.

[11]  F. Castellino,et al.  Conversion of Glu-Plasminogen to Lys-Plasminogen Is Necessary for Optimal Stimulation of Plasminogen Activation on the Endothelial Cell Surface* , 2001, The Journal of Biological Chemistry.

[12]  K. Hajjar,et al.  Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. , 2001, Blood.

[13]  D. Richardson,et al.  The membrane‐bound transferrin homologue melanotransferrin: roles other than iron transport? , 2000, FEBS letters.

[14]  E. Voest,et al.  No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. , 2000, European journal of cancer.

[15]  A. Houng,et al.  Epsilon amino caproic acid inhibits streptokinase-plasminogen activator complex formation and substrate binding through kringle-dependent mechanisms. , 2000, Biochemistry.

[16]  D. Richardson.  The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. , 2000, European journal of biochemistry.

[17]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[18]  T. Kawamoto,et al.  Expression of membrane-bound transferrin-like protein p97 on the cell surface of chondrocytes. , 1998, European journal of biochemistry.

[19]  M. Baker,et al.  Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. , 1998, British Journal of Cancer.

[20]  V. Schirrmacher,et al.  Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. , 1998, Experimental cell research.

[21]  M. Stack,et al.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin , 1997 .

[22]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[23]  W. Jefferies,et al.  Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium , 1996, Brain Research.

[24]  W. Jefferies,et al.  A novel iron uptake mechanism mediated by GPI‐anchored human p97. , 1995, The EMBO journal.

[25]  J. Hoover-Plow,et al.  The cell biology of the plasminogen system , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  K. Hajjar.  Cellular Receptors in the Regulation of Plasmin Generation , 1995, Thrombosis and Haemostasis.

[27]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. , 1994, The Journal of biological chemistry.

[28]  W. Jefferies,et al.  Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. , 1994, The Journal of biological chemistry.

[29]  F. Real,et al.  Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. , 1993, Journal of cell science.

[30]  H. Baker,et al.  Human melanotransferrin (p97) has only one functional iron‐binding site , 1992, FEBS letters.

[31]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[32]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[33]  K. Hajjar,et al.  Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. , 1988, The Journal of clinical investigation.

[34]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[35]  E. Jaffe,et al.  Binding of plasminogen to cultured human endothelial cells. , 1986, The Journal of biological chemistry.

[36]  W. Dreyer,et al.  Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Doolittle,et al.  Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.

[38]  J. Brown,et al.  Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. , 1981, Journal of immunology.

[39]  K. Hellström,et al.  Analysis of normal neoplastic human tissues for the tumor‐associated protein p97 , 1981, International journal of cancer.

[40]  J. Brown,et al.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Plow,et al.  Regulation of plasminogen receptors. , 2003, Frontiers in bioscience : a journal and virtual library.

[42]  C. Longstaff.  Plasminogen activation on the cell surface. , 2002, Frontiers in bioscience : a journal and virtual library.

[43]  J. Kovar,et al.  Role of melanotransferrin (p97) in non-transferrin iron uptake by HeLa and K562 cells. , 2000, Folia biologica.

[44]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[45]  J. Brown,et al.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.